Healthcare / Drug Manufacturers - Specialty & GenericTaiwan
$100.50
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $1.7B · quality 80.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$14.9B
P/E
12.3x
↓EV/EBITDA
3.9x
↓ROE
11.8%
↑Gross Margin
75.1%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-0.4%
FCF CAGR
-11.6%
FCF margin
16.7%
FCF / Net income
1.41x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $10.25B · net income $1.22B · FCF $1.72B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $10.25B | $10.25B | $11.16B | $10.64B | $10.39B |
| Net Income | $1.22B | $1.22B | $1.45B | $1.45B | $1.46B |
| EBITDA | $2.86B | $2.86B | $3.19B | $3.12B | $3.14B |
| EPS | 8.17 | 8.17 | 9.71 | 9.74 | 9.78 |
| Gross Margin | 75.1% | 75.1% | 77.6% | 80.3% | 81.6% |
| Operating Margin | 20.9% | 20.9% | 22.4% | 23.5% | 24.6% |
| Net Margin | 11.9% | 11.9% | 13.0% | 13.7% | 14.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Current Ratio | 1.60 | 1.60 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.72B | $1.72B | $1.23B | $1.92B | $2.49B |
| Returns | |||||
| ROE | 11.8% | 11.8% | 14.4% | 14.6% | 15.2% |
| Valuation | |||||
| P/E | 12.30 | 12.30 | 15.14 | 15.81 | 16.87 |
| EV/EBITDA | 3.86 | 3.86 | 5.56 | 5.87 | 6.40 |
| P/B | 1.45 | 1.45 | 2.18 | 2.30 | 2.57 |
| Growth & Yield | |||||
| Revenue Growth | -8.1% | -8.1% | 4.9% | 2.4% | — |
| EPS Growth | -15.9% | -15.9% | -0.3% | -0.4% | — |
| Dividend Yield | 6.0% | 6.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
3.0%
EPS terminal req.
$8.92
Spread vs growth
-18.8%
5Y implied EPS CAGR
5.7%
EPS terminal req.
$10.79
Spread vs growth
-21.6%
10Y implied EPS CAGR
7.8%
EPS terminal req.
$17.38
Spread vs growth
-23.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-19.6%
Start / end P/E
13.9x → 12.3x
EPS bridge
9.71 → 8.17
Residual
+1.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.